We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A UK-funded report is calling for drugmakers and regulators to create 15 new antibiotics every 10 years, at least four of them breakthrough products, to fight the rise in antibiotic resistant bacteria. Read More
India’s drugs price regulator is warning drugmakers that they’ll face fines and imprisonment if they don’t register immediately on an online database. Read More
The Saudi Food and Drug Authority has set strict new requirements for the import, clearance and export of commercial and investigational drugs, including provisions on drugs for compassionate use and drugs meant for use in clinical trials. Read More
The European Medicines Agency is taking a hard look at whether patients taking inhaled corticosteroids for chronic obstructive pulmonary disease are at higher risk for pneumonia. Read More
The European Medicines Agency is tightening its rules around conflicts of interest, barring individuals who take jobs in industry from serving on any of its advisory committees. Read More
Sponsors seeking Canadian approval of new drugs or indications based on published literature or postmarketing data need to be able to prove that their drug is comparable to its reference product, regulators say. Read More
Drugmakers are getting better at reporting clinical trials results in a timely manner, with only 10 percent of studies on new treatments approved by the European Medicines Agency in 2012 not disclosed within 12 months, a new study shows. Read More
The U.S. Food and Drug Administration increased its preapproval inspections of generics makers by 60 percent between fiscal years 2011 and 2013, but failed to conduct all of those requested by agency reviewers, a new report finds. Read More
The Therapeutic Goods Administration is considering raising the threshold for classifying rare diseases, as well as the number of patients in specific subsets of a disease, to broaden the scope of drugs that qualify for orphan status. Read More
The House Energy & Commerce Committee passed the 21st Century Cures Act on May 21, a measure that would extend the rare pediatric disease priority review voucher program from its current sunset date in March 2016 through December 2018. Read More
Sponsors of regenerative drugs can now get a conditional approval in Japan based on limited data, under a new regulatory pathway meant to speed patient access to novel therapies. Read More